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Mesenchymal stem cells (MSCs) are of special interest as therapeutic agents in the settings of both chronic inﬂammatory and
autoimmune diseases. Toll-like receptors (TLR) ligands have been linked with the perpetuation of inﬂammation in a number of
chronic inﬂammatory diseases due to the permanent exposure of the immune system to TLR-speciﬁc stimuli. Therefore, MSCs
employed in therapy can be potentially exposed to TLR ligands, which may modulate MSC therapeutic potential in vivo. Recent
results demonstrate that MSCs are activated by TLR ligands leading to modulation of the diﬀerentiation, migration, proliferation,
survival, and immunosuppression capacities. However inconsistent results among authors have been reported suggesting that the
source of MSCs, TLR stimuli employed or culture conditions play a role. Notably, activation by TLR ligands has not been reported
to modulate the “immunoprivileged” phenotype of MSCs which is of special relevance regarding the use of allogeneic MSC-based
therapies. In this review, we discuss the available data on the modulation of MSCs activity through TLR signalling.
1.Introduction
Adult mesenchymal stem cells (MSCs) represent an inno-
vative tool for cell-based therapy of degenerative disor-
ders, chronic inﬂammatory, and autoimmune diseases or
allograft rejection. The understanding of the mechanisms
that mediate and/or modulate the therapeutic potency of
MSCs is important from both a physiological and a clinical
point of view. In this context, one key interest is to better
understand the modulation of MSC biology by Toll-like
receptors (TLRs) as they have been linked to the perpetu-
ation of chronic inﬂammatory responses (Chron’s disease,
Rheumatoid Arthritis) through the recognition of conserved
pathogen-derived components or endogenous ligands (also
known as “danger signals”) that MSCs will likely encounter
inthesitesofinjury.Herewewillreviewthemostrecentdata
on these topics.
2. Adult Mesenchymal Stem Cells and
Cell Therapy
2.1. Diﬀerentiation Capacity of MSCs. MSCs have been
isolated from multiple tissues of mesodermal origin, such
as bone marrow (BM-MSCs), adipose tissue (AD-MSCs),
umbilical cord blood and peripheral blood. MSCs can be
easily isolated by adhesion to plastic and expanded in vitro
in serum containing media with no additional requirements
for growth factors or cytokines. In culture, they acquire
a ﬁbroblast-like morphology. Despite ample eﬀorts, no
exclusive surface markers have been identiﬁed for MSCs.
Thus, to date they are deﬁned according to the criteria of the
International Society for Cellular Therapy by being negative
for hematopoetic and endothelial markers such as CD11b,
CD14, CD31, CD34, and CD45, and positive for a variety of
many other markers, including HLA class I, CD105, CD73,
CD29, and CD90 [1]. Therefore, MSCs can be identiﬁed
in vitro by their ability to diﬀerentiate into mesenchymal-
type cells (adipocytes, osteoblasts, and chondrocytes) but
also neurons, endothelial cells, astrocytes, and epithelial cells
when cultured in the appropriate conditions [2–6].
2.2. Immunogenicity of MSCs. The expression of human
leukocyte antigen (HLA) molecules class I (also called
Mayor Histo-Compatibility class I = MHC I) on all cells
on the body allows the immune system to distinguish self
from nonself. In the absence of immune suppression or2 Mediators of Inﬂammation
tolerogenic mechanisms, allogeneic cells are rejected by the
immunesystemuponrecognitionoftheirforeignHLA.Cells
expressing HLA molecules stimulate T cells directly only
if they possess appropriate costimulatory molecules—CD80
(B7-1), CD86 (B7-2) or CD40-. Allogeneic cells can also
activate T cells through an indirect pathway where their HLA
antigens are presented by professional antigen presenting
cells (APC). Aside from HLA class I, certain cells also express
HLA class II constitutively or after induction. HLA II also
plays an important role in antigen presentation and immune
response. A remarkable unique feature of MSCs is that they
are considered to be immunoprivileged as they express low
levelsofcell-surfaceHLAclassImoleculeswhereasHLAclass
II, CD40, CD80, and CD86 are not detectable on the cell
surface. Stimulation with interferon (IFN)-γ has been shown
toincreasebothclassIandclassIImolecules,however,MSCs
do not express costimulatory molecules CD80 (B7-1), CD86
(B7-2)orCD40,evenafterIFN-γ stimulation.Thesefeatures
allow MSCs to escape to the immune surveillance [7–11].
MSCs not only fail to induce activation of CD4+ cells but
also escape lysis by CD8+ cytotoxic lymphocytes [12]. Even
whole lymphocytes stimulated in vitro to target Peripheral
Blood Lymphocytes (PBLs) derived from a speciﬁc donor,
will lyse lymphocytes from that individual but not MSCs
derived from the same donor. Further analyses indicate that
MSCs induce an abortive activation programme in fully
diﬀerentiated CD8+ T cells so that major eﬀector functions
are not activated. MSCs also escape natural killer (NK) cell-
speciﬁc lysis [12].
2.3.ImmunosuppressiveCapacityofMSCs. Athirdimportant
feature of MSCs is that they are immunosuppressive and
inhibit activation, proliferation, and function of immune
cells, including T cells, B cells, NK cells and antigen-
presenting cells (APCs) [6, 13–24]. Despite ample research
in recent years, mostly in BM-MSCs, the speciﬁc molecular
and cellular mechanisms involved in the immunoregulatory
activity of MSCs remain controversial. There is evidence
that the capability to modulate immune responses relies
on both cell contact-dependent mechanisms and soluble
factors secreted by MSCs in response to cytokines released
by activated immune cells. MSCs may inhibit lymphocyte
proliferation by a mechanism that requires, at least in part,
thereleaseofsolublefactorssuchashepatocytegrowthfactor
(HGF), prostanglandin-E2 (PGE2), transforming growth
factor (TGF)-β1, indoleamine 2,3-dioxygenase (IDO), nitric
oxide, and interleukin (IL)-10 [14, 16, 18, 21, 22, 25–29].
On the other hand, other studies have shown that BM-MSCs
may modulate T-cell phenotype resulting in the generation
of cells with regulatory activity [14, 15, 19, 30–34].
2.4. MSCs Treatment as a New Therapeutic Tool. The bio-
logical characteristics mentioned above make MSCs an
interesting tool for cellular therapy and regeneration. This
is supported by a number of studies in animal models of
inﬂammatory diseases demonstrating an eﬃcient protection
against allograft rejection, graft-versus-host disease, exper-
imental autoimmune encephalomyelitis, collagen-induced
arthritis, sepsis and autoimmune myocarditis [13, 28, 31–
38]. In fact, MSCs are being used in several clinical
trials with a focus on their immunomodulatory capacities
(http://clinicaltrials.gov/search/term=stem+cells?term=stem
+cells). In this regard, Cellerix is currently conducting a
phase III clinical trial using human AD-MSCs to treat
complex peri-anal ﬁstula in Crohn patients after having
successfully completed phase I and II trial with high
eﬃcacy rates [39, 40]. Importantly, it is believed that the
therapeutic potency, safety, and eﬃcacy of treatment of
inﬂammatory diseases with MSCs reside to a large extent
in their immunologically privileged phenotype and in their
immunosuppressive capacity. Interestingly, TLR activation
has been implicated in the pathology of a number of
inﬂammatory diseases including rheumatoid arthritis or
inﬂammatory bowel disease (IBD), since they can either
initiate or perpetuate the chronic inﬂammation due to the
continue exposure to TLR ligands [41, 42]. Therefore, the
use of MSCs in cell therapy for the treatment of inﬂam-
matory diseases deserves further investigation regarding
the potential eﬀects of TLR signaling on MSCs biology
and the potential implications in the immunogenicity and
immunosuppressive capacity, which are of special relevance
in terms of therapeutic potency.
3. Modulation of MSCs through TLRs
3.1. MSCs Express Active TLRs. Expression of TLRs at the
RNA and protein levels have been studied by RT-PCR, ﬂow
cytometry, and immunoﬂuorescence. It is well established
that MSCs express a number of TLRs. So far, consistent
results demonstrate high mRNA expression of TLR 1, 2, 3, 4,
5, and 6 in AD-MSCs and BM-MSCs from both human and
mice, while inconsistent results have been reported on the
expression of TLR 7 to 10 in the same studies. At the protein
level, expression of TLR2, TLR3, TLR4, TLR7, and TLR9 has
been reported by ﬂow cytometry and immunoﬂuorescence
[23, 28–31, 43].
Expression of TLRs can be modulated in MSCs. Thus,
Hwa Cho et al. have studied whether hypoxia can aﬀect the
expression of TLRs in human AD-MSCs, as these cells may
be used as a therapeutic approach in ischemic tissues [44].
They demonstrated that exposure to hypoxic conditions sig-
niﬁcantly increase mRNA of TLR1, 2, 5, 9, and 10. Moreover,
lipopolysaccharide (LPS) challenge downregulates TLR2 and
TLR4 expression in MSC-derived osteoprogenitors [45]. On
the other hand, transduction of MSCs with baculoviruses
(a DNA viral vector) upregulates expression of TLR3 and
triggers TLR3 signaling pathway [46].
As reviewed extensively somewhere else in this issue,
TLR activation trigger MyD88 dependent and independent
downstream signalling cascades leading to the nuclear
translocation of NF-κB and other transcription factors and
the activation of a number of genes (see Figure 1)[ 47–52].
It has been demonstrated that when AD-MSCs or BM-MSCs
were stimulated with ligands speciﬁc for diﬀerent TLRs the
n u c l e a rf a c t o r - k a p p aB( N F - κB), mitogen-activated protein
(MAP) kinases (MAPKs), PI3K signalling pathways wereMediators of Inﬂammation 3
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Figure 1: TLR signalling. Ligand recognition results in the recruitment of intracellular TIR-domain-containing adaptors proteins, including
myeloid-diﬀerentiationprimary-responseprotein88(MyD88,sharedbyallTLRs,exceptTLR3),andToll/IL-1Rdomain-containingadaptor-
inducing IFN-β (TRIF, employed by TLR3 and TLR4). Engagement of MyD88 activates a signaling cascade including IL-1R-associated
kinases (IRAKs,), (TNF)-receptor-associated factor 6 (TRAF6) and transforming growth factor-β (TGF-β)-activated kinase (TAK1), leading
to the activation of the mitogen-activated protein (MAP) kinases ERK, JNK, and p38, and nuclear translocation of the transcription factor
nuclear factor-κB( N F - κB) (MyD88-dependent pathway). There is a second, alternative pathway triggered by TRIF (MyD88-independent
pathway) that culminates in the activation of NF-κB, MAPKs, and the transcription factors interferon-responsive factors (IRFs), whose are
responsible for induction of type I IFNs, in particular IFNβ. Besides MyD88 and TRIF, two other adaptor proteins have been described: TIR-
domain-containing adaptor protein (TIRAP, also called MAL), and TRIF-related adaptor molecule (TRAM, required for TRIF-dependent
signaling through TLR4, but not TLR3).
activated with a subsequent induction of several genes and
cytokines, mainly CXCL-10, IL-6 and IL-8. These results
clearly demonstrate that MSC express active and functional
TLRs. However, diﬀerences in the induction of genes in
response to TLR activation have been reported. For instance,
in contrast to our observations in AD-MSC, Hwa Cho
et al., and Tomchuck et al. have reported the induction
of tumor necrosis factor (TNF)-α and IL-1β by LPS and
polyinosinic:polycytidylic acid (Poly IC) in BM-MSC and
AD-MSC, respectively [44, 53].
3.2. Eﬀect of TLR Activation on MSC Survival. In response to
TLR stimulation human AD-MSCs induce the expression of
manganesesuperoxidedismutase(MnSOD),akeyprotective
protein against oxidative stress in the mitochondria [23].
It has been reported that induction of MnSOD protects
cells from oxidative stress leading to increased survival [54].
In the settings of an inﬂammatory response, immune cells
release vast amounts of reactive oxygen species which results
in the generation of an oxidative milieu. Based on these
data we speculated that increased expression of MnSOD by
MSCs in response to TLR ligand exposure would provide
them with improved engraftment or survival at injured
or inﬂamed sites, leading to enhanced therapeutic eﬀects
[23]. This hypothesis is further supported by recent results
showing that TLR4 activation protects MSCs from oxidative
stress-induced apoptosis [55]. In fact, LPS preconditioning
of mouse BM-MSCs can, when compared to unconditioned
MSCs, improve their survival and engraftment of MSCs and
increase the release of vascular endothelial growth factor
(VEGF) in a model of rat acute myocardial infarction
leading to an enhanced therapeutic eﬀect (improved cardiac
function,reducedapoptosisofmyocardium,reducedﬁbrosis
and elevated vascular density after myocardial infarction)
[56] (see Table 1).
3.3. Eﬀect of TLR Triggering in the Diﬀerentiation of MSCs.
As indicated above, one of the main features of MSCs is the4 Mediators of Inﬂammation
potential to diﬀerentiate to several cell types of mesenchymal
origin. Some groups have reported the eﬀects of TLR activa-
tion on MSC diﬀerentiation with contradictory results. We
found no eﬀect on adipogenic diﬀerentiation but detected
that Poly I:C and LPS increased osteogenic diﬀerentiation
in human AD-MSCs [23]. However Hwa Cho et al. [44]
reported increased osteogenic diﬀerentiation of human AD-
MSC by LPS and peptidoglycan (PGN) activation, whereas
CpG oligodeoxynucleotides (CpG-ODN) impaired it. The
increased osteogenic diﬀerentiation in the presence of LPS or
PGN was accompanied by increased ERK activation. These
authors reported reduced adipogenic diﬀerentiation when
PGN was present. On the other hand, whereas Mo et al. [45]
reported increased osteogenic diﬀerentiation of human BM-
MSCs after prolonged LPS activation, Liotta et al. [57]f o u n d
no eﬀect of TLR activation on adipogenic, osteogenic or
condrogenic diﬀerentiation of human BM-MSCs. However,
Pevsner-Fischer et al. [58] reported that TLR2 activation by
Pam3Cys reduced mouse BM-MSC diﬀerentiation into the
three mesodermal lineages.
Interestingly, they also found that myeloid-differentia-
tion primary-response protein 88 (MyD88)-deﬁcient BM-
MSCs, when cultured in the appropriate diﬀerentiation
media without additional stimulation with TLR ligands
eﬀectively diﬀerentiated into adipocytes but failed to dif-
ferentiate into osteocytes and chondrocytes, indicating that
this pathway may be involved in MSC mutipotency. These
discrepancies could be due to diﬀerences in culture condi-
tions,betweenbonemarrowandadipose-derivedMSCs,and
between mouse and human cells (see Table 1).
3.4. Eﬀect of TLR Activation on Proliferation and Migration
of MSCs. The eﬀect of TLR activation in the proliferation
of MSCs has been studied by several groups. Stimulation
with LPS or Pam3Cys promoted proliferation of mouse
BM-MSCs [55, 58], but stimulation with LPS, Poly I:C,
lipoteichoic acid (LTA) and PGN showed not signiﬁcant
eﬀects on human AD-MSCs and BM-MSCs [23, 44, 45].
However, Hwa Cho et al. reported that stimulation of AD-
MSCs with CpG-ODNs leads to a G1 arrest wich results in
inhibition of proliferation [44] (see Table 1).
Migration to the appropriate site of injury is considered
to play an important role in the therapeutic eﬃcacy of
MSCs. In this context, Tomchuck et al. demonstrated
that TLR3 activation drives the migration of human BM-
MSCs using transwell and Boyden chamber migration
assays suggesting that this TLR signalling pathway may
be manipulated to increase the biodistribution of infused
MSCs at the injured sites [53]. Moreover, LPS, ODNs, LL-
37 (an antimicrobial peptide), ﬁbronectin fragment III 1C
(Fn III1C) and ﬂagellin resulted in moderate to limited
induced migration. On the other hand, Pevsner-Fischer et
al. found that TLR2 activation impaired mouse BM-MSC
migration using “wound healing” assays [58] (see Table 1).
Nevertheless, further investigation will be required to better
understand the potential role of TLR signalling in migration
andbiodistribution ofMSCsinvivo, whichisofgreatclinical
relevance.
3.5. TLRs and the Immunogenic Phenotype of MSCs. The
potentialuseofallogeneicMSCsreliesonthespecialcapacity
of these cells to escape to the immune recognition. It is
wellestablishedthatTLRactivationcanmodulateexpression
of costimulatory molecules in immune cells. Therefore, it
is of special interest from a therapeutic point of view to
determine whether exposure of MSCs to TLR ligands may
induce the expression of HLA-I, HLA-II, and costimulatory
molecules (CD40, CD80, CD86) leading to an augmented
immunogenic phenotype. We analyzed the expression of
HLA-I, HLA-II, CD80, and CD86 in human AD-MSCs by
ﬂow cytometry 72 hours after stimulation with LPS, Poly
I:C, and PGN. We found that LPS, Poly I:C, and PGN
did not alter the expression of HLA-II, CD80, and CD86.
Poly I:C was the only TLR ligand capable to induce HLA-
I to some extend. Furthermore, costimulation of human
AD-MSCs with IFN-γ (a well-known inducer of HLA-I and
HLA-II expression in MSCs) in combination with either
LPS, Poly I:C or PGN did not alter the INF-γ-mediated
induction of HLA-I and HLA-II [23]. Similar results have
also been reported in human BM-MSCs [43, 57]. These
results indicate that TLR activation does not signiﬁcantly
aﬀect the immunogenic properties of human MSCs (see
Table 1). These results are of great relevance regarding the
use of allogeneic MSC-based cell therapies.
3.6. Eﬀect of TLR Activation on the Immunosuppressive
Capacity of MSCs. BM-MSC and AD-MSCs have been
shown to possess the capacity to inhibit proliferation of
immune cells upon mitogenic or allogeneic activation. As
mentioned above, this immunosuppressive capacity of all
MSCs can become a key factor for their therapeutic use and
potency. The mechanisms underlying the immunosuppres-
sion potential of MSCs are not fully understood, but seem to
require both cell-to-cell contact-dependent mechanisms and
thereleaseofsolubleimmunemodulators(IDO,PGE2,TGF-
β1, nitric oxide, etc.) upon activation in response to immune
cells. Interestingly, some of these immune modulators are
downstream of signalling pathways triggered by TLRs in
other cell types. Therefore, a feasible hypothesis is that
TLR ligands may induce the production of such anti-
inﬂammatory mediators in MSCs resulting in an enhanced
immunosuppressive phenotype. Moreover, TLR signalling
has been associated with the perpetuation of chronic inﬂam-
matory and autoimmune diseases such as Crohn’s disease
and Rheumatoid Arthritis [41, 42]. Therefore, AD-MSCs
and BM-MSCs employed in the treatment of such diseases
will likely be exposed to TLR ligands, which may result in
the modulation of MSCs activity and therapeutic potency.
Therefore, it is very important to determine whether TLR
signalling may modulate the immunosuppressive capacity of
MSCs.
In recent years, several groups have reported inconsistent
results regarding the role of TLR ligands on the modulation
of MSCs capacity to suppress immune responses. In this
context,wetestedtheroleofTLRsintheimmunosuppressive
capacity of human AD-MSCs. To do so, we analyzed
proliferation of activated CFSE-labeled PBLs, CD4+ T cellsMediators of Inﬂammation 5
Table 1: Summary of reported eﬀects on MSC activity by TLR ligands.
Ligand Adipogenic Condrogenic Osteogenic Immuno-
genicity
Immuno-
suppression
Migration Proliferation Survival Source Species Ref
LPS
≈↑ ≈≈ ≈ AD Human [23]
≈↑ BM Human [43]
≈↑ ≈ AD Human [44]
↑≈ BM Human [45]
↑↑ BM Mouse [55]
↑ BM Mouse [56]
↑ BM Human [53]
≈≈≈ ≈↓ BM Human [57]
PolyIC
≈↑ ≈≈ ≈ AD Human [23]
≈↑ BM Human [43]
≈≈ ≈ AD Human [44]
↑ BM Human [53]
≈≈≈ ≈↓ BM Human [57]
PGN
≈≈ ≈≈ ≈ AD Human [23]
≈↑ ≈ AD Human [44]
CpG-
ODNs
≈≈ AD Human [23]
≈↓ ↓ AD Human [44]
↑ BM Human [53]
Flagellin
≈≈ AD Human [44]
↑ BM Human [53]
Pam3Cys ↓↓↓ ≈ ↓↑ BM Mouse [58]
LL-37 ↑ BM Human [53]
Fn III1C ↑ BM Human [53]
R-848 ≈≈≈ ≈≈ BM Human [57]
LTA ≈ BM Human [45]
≈ (no signiﬁcant eﬀect), ↑ (increase), ↓ (inhibition), AD (adipose derived MSCs), BM (Bone marrow MSCs). LPS: Lipopolysaccharide; PolyIC:
Polyinosinic:polycytidylic acid; PGN: Peptidoglycan; CpG-ODNs: CpG oligodeoxynucleotides; Fn III1C: Fibronectin fragment III 1C; LTA: Lipoteichoic acid.
and CD8+ T cells in the absence or presence of increasing
amountsofhumanAD-MSCspreculturedforupto72hours
with medium alone or in the presence of LPS, Poly I:C or
PGN. We found no signiﬁcant eﬀect of TLR activation on
humanAD-MSC-mediatedsuppression,indicatingthatacti-
vation through TLR2, TLR3, and TLR4 do not signiﬁcantly
interfere with the capacity of human AD-MSCs to modulate
immune responses in vitro. Supporting these results, IDO,
a key mediator of human AD-MSCs immunosuppression
[24] was weakly induced by a high concentration of Poly
I:C and was not induce upon TLR2 or TLR4 triggering
[23]. Similar results were reported by Pevsner-Fischer et
al., showing that TLR2 activation by Pam3Cys does not
aﬀectimmunosupressionmediatedbymouseBM-MSC[58].
However, other groups have reported that TLR activation
may modulate the immunosuppressive properties of human
BM-MSCs,althoughinverydiﬀerentways.Thus,Liottaetal.
found that TLR3 and TLR4 activation reduce the inhibitory
activity of human BM-MSCs on T-cell proliferation without
inﬂuencing IDO activity or PGE2 levels [57]. By using
inhibitors of the Notch signalling pathway and anti-Jagged-
1 neutralizing antibodies they found that TLR activation
leads to the downregulation of the Notch ligand Jagged-1 in
BM-MSCs. Based on these data, the authors suggested that
Notch signalling pathway mediates the cell contact-mediated
immunosuppression by MSCs. In contrast to these results,
Opitz et al. have recently reported that TLR3 and TLR4
engagement enhances the immunosuppressive properties
of human BM-MSCs through the indirect induction of
IDO1 [43]. Induction of IDO1 involved an autocrine IFN-
β signalling loop, which was dependent on protein kinase R
(PKR) and independent on IFN-γ.
A common characteristic of all MSCs is that they
constitutively express IL-6 and IL-8. The signiﬁcance of a
constitutive expression of IL-6 and IL-8, which can both
be considered proinﬂammatory cytokines, in context to
the immunosuppressive activity of MSCs is still unclear.
Interestingly, it has been reported that MSCs inhibit the
diﬀerentiation of dendritic cells, at least in part, through the
release of IL-6 [59]. This observation links IL-6 production
to the immunosuppression mediated by MSCs. Hence, it is
tempting to speculate that induction of IL-6 secretion by
TLR activation may enhance MSCs-mediated impairement
of dendritic cells diﬀerentiation and maturation.6 Mediators of Inﬂammation
These inconsistent and partly contradictory results
demonstrate the complexity of the immune system, even
under in vitro conditions. It is likely that diﬀerences in the
experimental settings between laboratories might be behind
these contradictory results (see Table 1). For instance, the
use of PBMCs versus puriﬁed T cells or the method of
activationofthesecellsmayplayarole.Liottaetal.employed
puriﬁed CD4+ T cells stimulated with allogeneic T cell-
depleted PBMCs and anti-CD3 mAb, Opitz et al. used a
mixed lymphocyte reaction (MLR) with total PBMC from
two unrelated donors, one of which was irradiated, and we
used either whole PBMC samples or puriﬁed CD4+ and
CD8+fractionsstimulatedwithbeadsloadedwithanti-CD3,
anti-CD2 and anti-CD28 mAbs. Another important aspect
could be the time of treatment with TLR ligands and the
concentration of them (very variable among studies). While
some left TLR ligands in the cocultures or pretreated the
MSCs with TLR ligands for several days before initiating
the coculture experiments [23, 57], others pretreated MSCs
for 24 hours, washed and cocultured them with the MLR
[43]. It has also been suggested that a long-term exposure to
TLR ligands may lead to downregulation of factors induced
shortly after activation of TLR [43].
AsseveralstudieshavereportedbeneﬁtialeﬀectsofMSCs
treatment in animal models of LPS-induced sepsis or lung
injury [32, 38, 60], an inhibition of a therapeutic capacity
of MSC by TLR ligands does not appear to be the case.
Thus, it is unclear whether in vivo potency of MSCs can be
potentiated by TLR ligands, however it does not appear to be
impaired.
4. Concluding Remarks
It is necessary to better deﬁne the role of TLR activation on
MSC biology in the context of the development of new ther-
apeutic strategies on inﬂammatory or autoimmune diseases,
simply because MSCs are likely be exposed to activation
through TLR ligands in the sites of injury or inﬂammation.
The discrepancies shown by diﬀerent authors need further
investigation as it would be relevant to determine whether
or not TLR activation interferes or enhances migration,
biodistribution or immunosuppressive capacity of MSCs.
Diﬀerences in the source of MSCs, type and concentration
of the stimuli used, the experimental settings and method of
detection or culture conditions may explain these discrep-
ancies. On the other hand, the recognition of endogenous
ligands by TLRs is now thought to have an important role
in the regulation of inﬂammation, both in infectious and
noninfectious diseases. A number of endogenous ligands
have been identiﬁed, including heat shock protein (HSP)
60, HSP 70, heparan sulfate, hyaluronan, ﬁbronectin extra
domain A,uric acid,oxidized LDL,intracellularcomponents
of fragmented cells, myeloid-related proteins-8 and 14,
eosinophil-derived neurotoxin, and human defensin-3 [61–
72]. As these ligands are accessible to TLRs in the setting
of injury or non-infectious threat, they have been called
“danger signals”. A very important aspect that has not been
studied in details so far is the activation and modulation of
MSC activity by these danger signals. Given the capacity of
MSCstomodulateimmuneresponsesitwouldbeinteresting
to determine whether resident MSCs may be activated by
danger signals in the settings of injury and if this activation
results in a contribution of MSCs to the process of healing
and cure in homeostasis.
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